PRAX Quote, Financials, Valuation and Earnings

Celcuity, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of --. Praxis Precision Medicines, Inc.'s return on equity of -60.4% beat Celcuity, Inc.'s return on equity of -158.5%.

Praxis Precision Medicines, Inc. has a consensus price target of $600.71, signalling upside risk potential of 78.38%. On the other hand Celcuity, Inc. has an analysts' consensus of $116.70 which suggests that it could grow by 4.47%. Given that Praxis Precision Medicines, Inc. has higher upside potential than Celcuity, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than Celcuity, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.859, which suggesting that the stock is 185.918% more volatile than S&P 500. In comparison Celcuity, Inc. has a beta of 0.382, suggesting its less volatile than the S&P 500 by 61.833%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celcuity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Celcuity, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Celcuity, Inc. quarterly revenues of --. Praxis Precision Medicines, Inc.'s net income of -$88.9M is lower than Celcuity, Inc.'s net income of -$43.8M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Celcuity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 930.95x versus -- for Celcuity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -124.5%. Praxis Precision Medicines, Inc.'s return on equity of -60.4% beat Insmed, Inc.'s return on equity of -192.35%.

Praxis Precision Medicines, Inc. has a consensus price target of $600.71, signalling upside risk potential of 78.38%. On the other hand Insmed, Inc. has an analysts' consensus of $212.53 which suggests that it could grow by 42.32%. Given that Praxis Precision Medicines, Inc. has higher upside potential than Insmed, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than Insmed, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.859, which suggesting that the stock is 185.918% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.131, suggesting its more volatile than the S&P 500 by 13.112%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Praxis Precision Medicines, Inc.'s net income of -$88.9M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 930.95x versus 48.98x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -82.97%. Praxis Precision Medicines, Inc.'s return on equity of -60.4% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34%.

Praxis Precision Medicines, Inc. has a consensus price target of $600.71, signalling upside risk potential of 78.38%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $140.67 which suggests that it could grow by 52.77%. Given that Praxis Precision Medicines, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.859, which suggesting that the stock is 185.918% more volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.058, suggesting its more volatile than the S&P 500 by 105.795%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $57.3M. Praxis Precision Medicines, Inc.'s net income of -$88.9M is lower than Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 930.95x versus 31.75x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -77256.06%. Praxis Precision Medicines, Inc.'s return on equity of -60.4% beat Viridian Therapeutics, Inc.'s return on equity of -53.74%.

Praxis Precision Medicines, Inc. has a consensus price target of $600.71, signalling upside risk potential of 78.38%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $41.76 which suggests that it could grow by 41.95%. Given that Praxis Precision Medicines, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than Viridian Therapeutics, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.859, which suggesting that the stock is 185.918% more volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.176%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $132K. Praxis Precision Medicines, Inc.'s net income of -$88.9M is higher than Viridian Therapeutics, Inc.'s net income of -$102M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 930.95x versus 35.15x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.